| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CryoPort, Inc. Common Stock$14.76
-0.01 (-0.07%)
Market Cap
482.11 M
EPS
-0.93
P/E Ratio
-10.37 $
Value Trade
36.39 M
SEC Financials
Q4 2025Dilution Risk
Revenue
45.45 M
R&D Expenses
4.47 M
Operating CF
-2.15 M
Total Assets
764.99 M
Total Liabilities
262.35 M
Equity
502.64 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
411.21 M
Monthly Burn
715.00 K
Runway
574.9 mo
Burn Trend
SEC Filing
Mar 5, 2026
Overview
Volume
443.68 K
52 Week Range
5.21 - 11.45
% held by Insiders
4.59 %
% held by Institutions
90.83 %
Enterprise Value
343.89 M
Total Shares
50.19 M
Short %
4.8 %
Float Shares
48.24 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CYRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CryoPort, Inc. Common Stock (CYRX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CYRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CYRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CYRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CYRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CYRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CYRX
May 4, 2026Cryoport Reports First Quarter 2026 Financial Results First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting cont
Cryoport, a leading provider of temperature-controlled supply chain solutions, reported a 16% increase in revenue for Q1 2026, totaling $47.8 million. The company's commercial support for cell and gene therapies grew by 26%, indicating strong market demand. As part of its growth strategy, Cryoport plans to expand its operations with new Global Supply Chain Centers in Paris and California. The firm has also raised its revenue guidance for the year, reflecting optimism about sustained growth in the future.
Read more →-CYRX
Apr 20, 2026Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
Cryoport, Inc. will report its financial results for Q1 2026 on May 4, 2026. A review document will accompany the earnings release, and a conference call will follow to address investor questions. The company emphasizes its role in providing integrated temperature-controlled supply chain solutions for the life sciences.
Read more →-CYRX
Mar 3, 2026Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2
Cryoport, Inc. (NASDAQ: CYRX) announced its financial results for Q4 and FY 2025, reporting a significant increase in revenue to $176.2 million, surpassing previous guidance. The company's Life Sciences Services revenue saw an 18% growth year-over-year, bolstered by a 29% rise in revenue from commercial cell and gene therapies. Cryoport supported a record 760 global clinical trials and established strategic partnerships to enhance its market position. Looking ahead, the company projects a revenue range of $190 million to $194 million for FY 2026.
Read more →-CYRX
Nov 4, 2025Cryoport Reports Third Quarter 2025 Financial Results Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences
Cryoport, Inc. has reported a 15% increase in third-quarter revenue, reaching $44.2 million, with significant contributions from cell and gene therapies. The company experienced notable growth in both Life Sciences Services and Products segments, with the former growing by 16% year-over-year. CEO Shelton indicated that the firm is well-positioned for profitability, raising its full-year revenue guidance due to promising performance and expansion initiatives. Additionally, a partnership with DHL is expected to enhance operations in the EMEA and APAC regions.
Read more →-CYRX
Aug 5, 2025Cryoport Reports Second Quarter 2025 Financial Results Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Science
Cryoport, Inc. reported a 14% increase in total revenue for Q2 2025, totaling $45.5 million, boosted by a 33% rise in revenue from supporting commercial cell and gene therapies. The company's Life Sciences Services revenue also showed robust growth, with a 21% year-over-year increase. A strategic partnership with DHL aims to enhance Cryoport's global biologistics capabilities while the company reaffirms its full-year revenue guidance, indicating confidence in sustainable profitability moving forward. The overall performance underscores Cryoport's strong positioning within the regenerative medicine market.
Read more →-CYRX
Jun 12, 2025Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
Cryoport, Inc. has completed the divestiture of its specialty courier business, CRYOPDP, to DHL Group, receiving around $200 million in cash. In addition, Cryoport and DHL have formed a strategic partnership to enhance supply chain service offerings for the life sciences sector. This collaboration aims to leverage Cryoport's expertise along with DHL's global logistics infrastructure, particularly in regions like Asia Pacific and EMEA. The company anticipates that this move will improve its growth trajectory and ensure a stronger position in the evolving market for regenerative medicine.
Read more →-CYRX
May 7, 2025Cryoport Reports First Quarter 2025 Financial Results Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Suppo
Cryoport, Inc. reported its financial results for the first quarter of 2025, achieving revenues of $41 million from continuing operations, reflecting a 10% increase compared to the previous year. The company also highlighted a 33% increase in revenues from supporting commercial Cell & Gene therapies. CEO Jerrell Shelton expressed optimism regarding future growth and stability within their services. Additionally, a strategic partnership with DHL is expected to further enhance operational capabilities, particularly in the APAC and EMEA regions.
Read more →-CYRX
Mar 31, 2025DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics" DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cel
DHL Group has announced its acquisition of 100% of CRYOPDP, a specialty courier that specializes in logistics for clinical trials and biopharmaceuticals. This move aims to bolster DHL's capabilities in the life sciences and healthcare sectors as part of its strategy to be a leader in related logistics services by 2030. Additionally, a strategic partnership with Cryoport has been established to further enhance their supply chain offerings. The deal underscores DHL's commitment to improving service levels and expanding its global footprint in the healthcare logistics market.
Read more →-CYRX
Mar 4, 2025Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-ove
Cryoport, Inc. reported its financial results for Q4 and FY 2024, with total revenue reaching $228.4 million, consistent with prior guidance. Notably, revenue from commercial Cell & Gene therapies increased by 20% for the fiscal year, highlighting growth in that sector. The company also reported a 45.8% gross margin for Q4 2024, an improvement from the same period last year. However, total revenue saw a slight decrease compared to FY 2023, primarily due to a decline in Life Sciences Products revenue. Cryoport aims for a revenue increase to between $240 - $250 million in FY 2025 based on ongoing strategic initiatives.
Read more →-CYRX
Nov 7, 2024Cryoport Reports Third Quarter 2024 Financial Results Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global cli
Cryoport, Inc. reported its third quarter financial results for 2024, showing a 9% increase in Life Sciences Services revenue and a 12% rise in BioStorage/BioServices revenue compared to the previous year. The company maintains its full-year revenue forecast of $225 million to $235 million despite a decline in Life Sciences Products revenue. CEO Jerrell Shelton highlighted strategic cost reduction measures and the launch of a new cryopreservation solution as key steps towards achieving sustainable profitability by 2025. However, challenges in product sales and external market conditions remain a concern.
Read more →-CYRX
Aug 6, 2024Cryoport Reports Second Quarter 2024 Financial Results Revenue improved sequentially across all businesses Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 gl
Cryoport, Inc. reported its financial results for Q2 2024, highlighting a sequential increase in revenue across all business segments. The company's commercial Cell & Gene Therapy revenue saw a significant boost of 51% compared to the previous year. However, the Life Sciences Products division experienced a decline due to lower demand. The company has revised its full-year revenue guidance to a range of $225 million to $235 million, citing ongoing operational improvements and cost management initiatives.
Read more →-CYRX
Aug 6, 2024Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes $200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasin
Cryoport, Inc. has announced a new repurchase program authorized for up to $200 million, which will be effective from August 1, 2024, through December 31, 2027. In addition, the company is repurchasing $160 million of its Convertible Senior Notes due in 2026, which is part of the new program and will strengthen its balance sheet. The repurchases are expected to close on August 9, 2024, while the company retains a substantial amount of liquidity to support long-term goals. Overall, these actions reflect Cryoport's strategic focus on debt management and long-term financial stability.
Read more →-CYRX
May 7, 2024Cryoport Reports First Quarter 2024 Financial Results Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A t
Cryoport, Inc. announced its Q1 2024 financial results, reporting total revenue of $54.6 million, a 13% decrease from the previous year. The Company noted a 9% increase in revenues from its Commercial Cell & Gene Therapy sector. Despite a challenging global environment leading to disappointing results for Life Sciences Products, the CEO expressed optimism about potential revenue growth as new therapies gain approvals. The Company is maintaining its full-year revenue guidance while implementing cost-cutting measures in light of current economic conditions.
Read more →-CYRX
Mar 12, 2024Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results FY 2023 revenue of $233.3 million, in-line with guidance Year- over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices reven
Cryoport, Inc. reported FY 2023 financial results, achieving total revenues of $233.3 million, which fell within their guidance range. The company saw notable growth in its service sectors, particularly in Cell & Gene Therapy, which increased by 33% from the previous year. Additionally, Cryoport supported a record number of clinical trials, indicating strong demand for its services, while facing challenges in product revenues and slight revenue declines in certain segments. Looking ahead, the company anticipates continued revenue growth in 2024, propelled by strategic investments and industry trends.
Read more →-CYRX
Nov 8, 2023Cryoport Reports Third Quarter 2023 Financial Results Third quarter 2023 commercial Cell and Gene Therapy revenue up 54% year-over-year Supporting a record total of 670 clinical trials worldwide, with 81 in Phase 3 Nine
Cryoport, Inc. reported its financial results for the third quarter and the first nine months of 2023, showcasing a 54% increase in commercial cell and gene therapy revenue year-over-year. Despite a 7% decrease in total revenue for Q3, the company achieved strong gross margins and supported a record number of clinical trials. Furthermore, Cryoport announced strategic partnerships and an acquisition aimed at bolstering its market position. However, operating costs have risen substantially due to increased investments in infrastructure and technology.
Read more →-CYRX
Aug 9, 2023Cryoport Reports Second Quarter 2023 Financial Results Second quarter revenue of $57 million, in line with previously announced preliminary results Clinical trials supported by Cryoport increased to a record 668 global c
Cryoport, Inc. announced its Q2 2023 financial results, reporting a revenue of $57 million, which marks an 11% decrease compared to Q2 2022. The decline in revenue was largely attributed to a 67% drop in business from its MVE Biological Solutions segment in China. Despite this short-term challenge, the company highlighted its expansion in clinical trials and revenue growth in certain segments, including bioservices. Looking forward, Cryoport remains optimistic about its long-term growth strategies in the cell and gene therapy market.
Read more →-CYRX
Jul 12, 2023Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start
Cryoport, Inc. announced its preliminary results for Q2 2023, expecting total revenue between $56.5 to $57.5 million, an 11% decrease from the previous year. The company's outlook has been revised downwards for full-year revenue due to weaker demand, delays in clinical trials, and disappointing performance from key clients. CEO Jerrell Shelton remains optimistic about long-term growth prospects in the cell and gene therapy sector, citing strong fundamentals and encouraging advancements among clients.
Read more →-CYRX
May 4, 2023Cryoport Reports First Quarter 2023 Results Record revenue of $63 million, representing 20% growth year-over-year Growth across all lines of business: Biopharma/Pharma revenue up 19%; Animal Health revenue up 30%; Reprod
Cryoport, Inc. reported record revenue of $62.8 million for the first quarter of 2023, marking a 20% increase compared to the previous year. The growth was driven by significant demand across its markets, particularly in Biopharma/Pharma and Animal Health. The company is well-positioned to support the expanding cell and gene therapy market with numerous clinical trials and planned new product launches. Looking forward, Cryoport anticipates sustained momentum despite current geopolitical challenges.
Read more →-CYRX
Feb 23, 2023Cryoport Reports Fourth Quarter and Full Year 2022 Results 2022 revenue reached a record $237 million, commercial revenue up 27% year-over-year Now supporting a record 654 global clinical trials and 10 commercial therapi
Cryoport, Inc. reported a record revenue of $237.3 million for 2022, a 7% increase from the previous year, driven by a 24% rise in revenue from Cryoport Systems. The company supported a total of 654 global clinical trials by year-end, reflecting strong demand in the cell and gene therapy market. Despite challenges including a fire at their Minnesota facility, Cryoport anticipates continued growth with projected revenues of $270 million to $290 million for 2023, bolstered by strategic partnerships and expanded service offerings.
Read more →-CYRX
Nov 3, 2022Cryoport Reports Results for the Third Quarter 2022 Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems' revenue up 25% year-over-year $530 million in cash and short-
Cryoport Reports Results for the Third Quarter NASHVILLE, Tennessee, November 3, 2022, - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial resu
Read more →-CYRX
Aug 4, 2022Cryoport Reports Results for the Second Quarter 2022 Record revenue of $64.2 million for the quarter, up 14% as reported and 18% at constant currency (year-over-year) Supporting a record 626 global clinical trials; a net
Cryoport Reports Results for the Second Quarter NASHVILLE, Tennessee, August 4, 2022, - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial resul
Read more →-CYRX
May 5, 2022Cryoport Reports First Quarter 2022 Results Revenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260-$265 million Expansion and advancement of robust clinical pipeline continues - now supporting a record
First Quarter 2022 Results NASHVILLE, Tennessee, May 5, 2022, - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months
Read more →-CYRX
Mar 11, 2022Cryoport Authorizes $100 Million Repurchase Program --- Management Presenting at Upcoming Investor Conferences
Cryoport Authorizes $100 Million Repurchase Program Management Presenting at Upcoming Investor NASHVILLE, Tennessee, March 11, 2022 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sc
Read more →-CYRX
Feb 24, 2022Cryoport Reports Fourth Quarter and Full Year 2021 Results 2021 annual revenue grew to $222.6 million, representing 183% year-over-year growth Cryoport Systems and CRYOGENE revenue grew 34% year-over-year for the fourth
Cryoport Reports Fourth Quarter and Full Year Tennessee, February 24, 2022 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the
Read more →-CYRX
Feb 9, 2022Cryoport Provides Positive Update on MVE Biological Solution's New Prague Facility Production Expected to Resume Week of
Cryoport Provides Positive Update on MVE Biological Solution's New Prague Facility Production Expected to Resume Week of NASHVILLE, Tennessee, February 9, 2022 - Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply cha
Read more →-CYRX
Jan 31, 2022Cryoport Reports Fire Damage at MVE's New Prague Facility
Cryoport Reports Fire Damage at MVE's NASHVILLE, Tennessee, January 31, 2022 - Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today reports that on January 25, 2022,
Read more →-CYRX
Nov 9, 2021Cryoport, Inc. Prices Upsized $350.0 Million Convertible Senior Notes Offering NASHVILLE, TENNESSEE-(PR NEWSWIRE)
Cryoport, Inc. Prices Upsized $350.0 Million Convertible Senior Notes Offering NASHVILLE, TENNESSEE-(PR NEWSWIRE)-November 9, 2021-Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced t
Read more →-CYRX
Nov 8, 2021Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering NASHVILLE, TENNESSEE-(PR NEWSWIRE)
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering NASHVILLE, TENNESSEE-(PR NEWSWIRE)-November 8, 2021-Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its intentio
Read more →-CYRX
Nov 4, 2021Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021 Third quarter revenue increased 407% year over year, reaching $56.7 million; Nine Months 2021 revenue $166.2 million Organic Revenue Growth of 38% co
Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021 NASHVILLE, Tennessee, November 4, 2021 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today
Read more →-CYRX
Aug 5, 2021Cryoport Reports Record Second Quarter 2021 Revenue Record Revenue for Second Quarter of 2021 of $56.2 million Revenue increased 498% year over year, with continuing strong performance by MVE Biological Solutions and CRY
Cryoport Reports Record Second Quarter 2021 NASHVILLE, Tennessee, August 5, 2021 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results fo
Read more →-CYRX
May 4, 2021Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021 Revenue increased 445% compared with Q1 2020, with acquisitions of MVE Biological Solutions and CRYOPDP driving significant growth Organic revenue growth of
Cryoport Revenue Climbs to $53.3 Million for Tennessee, May 4, 2021 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three-mo
Read more →-CYRX
Mar 3, 2021Cryoport Announces Appointment of Linda Baddour to its Board of Directors Ms. Baddour brings over twenty years of experience across healthcare, life sciences and pharmaceuticals
Cryoport Announces Appointment of Linda Baddour to its Board of Directors Ms. Baddour brings over twenty years of experience across healthcare, life sciences and pharmaceuticals NASHVILLE, Tennessee, March 3, 2021 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company")
Read more →-CYRX
Mar 1, 2021Cryoport Reports Record Results for Full Year 2020 Fourth quarter revenue increased 423% to $48.4 million, annual revenue increased 132% to $78.7 million Organic growth in revenue was 36% for the fourth quarter and 26% f
Record Results for Full Year 2020 Fourth quarter revenue increased 423% to $48.4 million, annual revenue increased 132% to $78.7 million Organic growth in revenue was 36% for the fourth quarter and 26% for the full year 2020 Cryoport is supporting a total of 528 clinical t
Read more →-CYRX
Feb 8, 2021Blackstone Converts $51 million of Cryoport Series C Preferred Stock Into Common Stock
$51 million of Cryoport Series C Preferred Stock Into Common Stock February 8, 2021 - Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that funds affilia
Read more →-CYRX
Jan 20, 2021You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statement
CAUTIONARY NOTE REGARDING FORWARD-LOOKING This Exhibit 99.1 contains forward-looking statements that have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actu
Read more →-CYRX
Dec 31, 2020Cryoport, Inc. All Rights Reserved CYRX: NASDAQ 2021 Cryoport, Inc. All Rights Reserved Forward Looking Statements Statements in this presentation and statements made orally during this presentation are not purely histor
Dec 2019 73% Revenue growth Jan 2019 Recognized leader for C> logistics; Supporting first two commercialized CAR T - cell therapies: Commercial launch of Tecartus, Cryoport supported therapy July 2020 Oct 2020 Cryoport completes two acquisitions: CRYOPDP, a global provider of t
Read more →-CYRX
Nov 5, 2020Cryoport Reports 2020 Third-Quarter Results Acquired MVE Biological Solutions and CRYOPDP advancing Cryoport's position as the global leader in temperature-controlled supply chain solutions for the life sciences industry
Cryoport Reports 2020 Third-Quarter NASHVILLE, Tennessee (November 5, 2020) - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport", "our" or "we"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced financial results for the Third Q
Read more →-CYRX
Oct 1, 2020Cryoport Completes Acquisitions of MVE Biological Solutions and CRYOPDP Cryoport fortifies its position as a leading global provider of temperature-controlled life sciences solutions with a combined revenue run rate of o
Cryoport Completes Acquisitions of MVE Biological Solutions and CRYOPDP Cryoport fortifies its position as a leading global provider of temperature-controlled life sciences solutions with a combined revenue run rate of over $160 million Blackstone invests $275 million NASHVI
Read more →-CYRX
Aug 25, 2020SCIENCE.
Cryoport Announces Agreement to Acquire MVE Biological Solutions from Chart Industries Cryoport will become a leading global provider of cryogenic life sciences solutions Acquisitions of MVE, along with CRYOPDP is expected to increase Cryoport's revenue run rate to over $160
Read more →-CYRX
Aug 21, 2020Cryoport Expands Global Supply Chain Platform by Signing Agreement to Acquire CRYOPDP Acquisition will expand Cryoport's presence in both the EMEA and APAC regions and broaden Cryoport's range of temperature-controlled s
Cryoport Expands Global Supply Chain Platform by Signing Agreement to Acquire CRYOPDP Acquisition will expand Cryoport's presence in both the EMEA and APAC regions and broaden Cryoport's range of temperature-controlled supply chain solutions for the life sciences; Upon closin
Read more →-CYRX
Aug 6, 2020Cryoport Reports 2020 Second-Quarter Results Revenue from commercial therapies increased 38% over the prior year 26 net clinical trial adds, now supporting 491 clinical trials in Regenerative Medicine market NASHVILLE, T
Cryoport Reports 2020 Second-Quarter Revenue from commercial therapies increased 38% over the prior year 26 net clinical trial adds, now supporting 491 clinical trials in Regenerative Medicine market NASHVILLE, Tennessee (August 6, 2020) - Cryoport, Inc. (NASDAQ: CYRX) ("Cr
Read more →-CYRX
May 19, 2020Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering NASHVILLE, Tennessee-(PRNewswire)
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering NASHVILLE, Tennessee-(PRNewswire)-May 19, 2020-Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced its intention to offer, subject to market and other conditions, $100.0 million in aggregate principal
Read more →-CYRX
May 7, 2020Cryoport Revenue Grows 47% for First Quarter 2020 ---- Revenue from commercial therapies increased 110% over the prior year 29 clinical trials added, now supporting 465 clinical trials in Regenerative Medicine market
Cryoport Revenue Grows 47% for Revenue from commercial therapies increased 110% over the prior year 29 clinical trials added, now supporting 465 clinical trials in Regenerative Medicine market NASHVILLE, Tennessee, May 7, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW)
Read more →-CYRX
Mar 5, 2020Cryoport Reports Record Revenue for Fiscal Year 2019 ---- Revenue grows 73% year over year Revenue from commercial therapies increased 295% over the prior year to $8.3 million Cryoport now supports 436 clinical trials in
Cryoport Reports Record Revenue for Fiscal Year 2019 Revenue grows 73% year over year Revenue from commercial therapies increased 295% over the prior year to $8.3 million Cryoport now supports 436 clinical trials in Regenerative Medicine marke NASHVILLE, Tennessee, March 5
Read more →-CYRX
Dec 31, 2019Cryoport Announces Preliminary Fourth Quarter and Full Year 2019 Revenue ---- 2019 Revenue Grows 73%, BioPharma Revenue Grows 64% NASHVILLE, Tennessee, January 9 th , 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW)
Cryoport Announces Preliminary Fourth Quarter and Full Year 2019 Revenue 2019 Revenue Grows 73%, BioPharma Revenue NASHVILLE, Tennessee, January 9th, 2020 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics compan
Read more →-CYRX
Nov 7, 2019Cryoport Revenue Grows 81% for Third Quarter 2019 ---- Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequen
Cryoport Revenue Grows 81% for Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially IRVINE, California, November 7, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NA
Read more →-CYRX
Oct 9, 2019Cryoport Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences
Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences California, October 9, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences in
Read more →-CYRX
Aug 8, 2019Cryoport Revenue Grows 83% for Second Quarter 2019 ---- Cryoport now supports 413 clinical trials in regenerative medicine Cryoport supports the commercial launch of bluebird bio's Zynteglo in Europe
Cryoport Revenue Grows 83% for Cryoport now supports 413 clinical trials in regenerative medicine Cryoport supports the commercial launch of bluebird bio's Zynteglo in Europe IRVINE, California, August 8, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), th
Read more →-CYRX
Jun 19, 2019Cryoport Announces Proposed Public Offering of Common Stock
Cryoport Announces Proposed Public Offering IRVINE, Calif., June 19, 2019 /PRNewswire/ - Cryoport, Inc. (Nasdaq: CYRX) (Nasdaq: CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer shares of common stock in an underwritten public offering under an effe
Read more →-CYRX
May 14, 2019Cryoport Expands into Biostorage through the Acquisition of Cryogene --- Acquisition is expected to be accretive to earnings and brings new industry-leading clients to Cryoport --- Acquisition expands Cryoport's offering
Cryoport Expands into Biostorage through the Acquisition of Cryogene Acquisition is expected to be accretive to earnings and brings new industry-leading clients to Cryoport Acquisition expands Cryoport's offerings to include biostorage solutions for life sciences commodities
Read more →-CYRX
May 2, 2019Cryoport Revenue Grows 65% for First Quarter 2019 ---- Commercial revenue rises to 25% of total biopharma revenue; 383 clinical trials supported
Cryoport Revenue Grows 65% for Commercial revenue rises to 25% of total 383 clinical trials supported IRVINE, California, May 2, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company d
Read more →-CYRX
Mar 7, 2019Cryoport Reports 64% Growth for Fiscal Year 2018 - - - Cryoport now supports 357 clinical trials in the Americas and EMEA with 47 in Phase
Cryoport Reports 64% Growth for Cryoport now supports 357 clinical trials in the Americas and EMEA with 47 in Phase III IRVINE, California, March 7, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled
Read more →-CYRX
Jan 7, 2019Cryoport Appoints Daniel M. Hancock to Board of Directors
Cryoport Appoints Daniel M. Hancock to IRVINE, California, January 7, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, is pleased to announce the appointment
Read more →-CYRX
Dec 17, 2018Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management
17Cryoport Announces $25 Million Petrichor Healthcare Capital Management IRVINE, Calif., December 17, 2018 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industr
Read more →-CYRX
Mar 6, 2018Cryoport Reports 56% Revenue Growth for Fiscal Year Ended
Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017 Cryoport added 85 new biopharma trials Cryoport now supports a total of 214 trials with 26 Phase III clinical trials IRVINE, California, March 6, 2018 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW)
Read more →-CYRX
Aug 8, 2017Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma - - - Biopharma revenue up 69% year-over-year; 33 new clinical trials supported during second quarter IRVINE, CA
Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma Biopharma revenue up 69% year-over-year; 33 new clinical trials supported during second quarter IRVINE, CA - Aug 8, 2017 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistic
Read more →-CYRX
Nov 3, 2016Cryoport Completes Warrant Tender Offer ------ Irvine, CA
Cryoport Completes Warrant Tender Offer Irvine, CA, November 03, 2016 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced it has received gross proceeds o
Read more →-CYRX
Aug 15, 2016Cryoport Continues to Climb, Reporting 34% Revenue Growth for the First Quarter of Fiscal Year 2017 - - - Company added 28 new biopharma clients during first three months of FY2017 and is supporting 23 of 28 leading CAR-
Cryoport Continues to Climb, Reporting 34% Revenue Growth for the First Quarter of Fiscal Company added 28 new biopharma clients during first three months of FY2017 and is supporting 23 of 28 leading CAR-T projects IRVINE, CA - August 15, 2016 - Cryoport, Inc. (NASDAQ: CYRX
Read more →-CYRX
Jun 27, 2016Cryoport Reports 50% Revenue Growth for Fiscal Year 2016 - - - Company is now supporting first commercial biologic therapy and 78 clinical trials IRVINE, CA
Cryoport Reports 50% Revenue Growth for Fiscal Year 2016 Company is now supporting first commercial biologic therapy and 78 clinical trials IRVINE, CA - June 27, 2016 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") today announced financial results for t
Read more →-CYRX
Jun 21, 2016Cryoport Successfully Completes Its Rights Offering --- Irvine, CA
Successfully Completes Its Rights Offering Irvine, CA, June 21, 2016 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"), the world's leading cryogenic logistics company, announced that it has received gross proceeds of $1,304,748 in subscriptions for 841,773 shares of comm
Read more →-CYRX
Feb 8, 2016Cryoport Reports 50% Revenue Growth for the Third Quarter of Fiscal Year 2016 - - - Company Adds 98 New Biopharma Clients During First Nine Months of FY2016 - - - 58% Revenue Growth for the First Nine Months of FY2016 -
Cryoport Reports 50% Revenue for the Third Quarter of Fiscal Company Adds 98 New Biopharma Clients During First Nine Months of FY2016 58% Revenue Growth for the First Nine Months of FY2016 Full Year Revenue Guidance Revised IRVINE, CA - February 8, 2016 - Cryoport, Inc. (
Read more →-CYRX
Nov 16, 2015Cryoport Revenues Climb 74% for the Second Quarter of Fiscal Year 2016 - - - Company Adds Over 160 New Customers in First Half of FY2016 - - - 63% Revenue Growth for the First Half of FY2016; Full Year Revenue Guidance C
Cryoport Revenues Climb 74% for the Company Adds Over 160 New Customers in First Half of FY2016 63% Revenue Growth for the First Half of FY2016; Full Year Revenue Guidance Confirmed LAKE FOREST, CA - November 16, 2015 - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Comp
Read more →-CYRX
Oct 1, 2015Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors - - - Conference call scheduled for 4:30 p.m. ET on Monday, October 5 th to introduce Dr. Hariri Lake Forest, CA
Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors Conference call scheduled for 4:30 p.m. ET on Monday, October 5th to introduce Dr. Hariri Lake Forest, CA, October 1, 2015 - Cryoport, Inc. (NASDAQ: CYRX) ("Company") today announced the appointment of Robert
Read more →-CYRX
May 19, 2015Cryoport Reports Record Revenues For Fourth Quarter and Fiscal Year 2015 - - - Strong performance in cryogenic logistics solutions and increase in customer base drives revenue growth of 44% for 4Q and 48% for FY2015 - -
Cryoport Reports Record Revenues For Fourth Quarter and Fiscal Strong performance in cryogenic logistics solutions and increase in customer base drives revenue growth of 44% for 4Q and 48% for FY2015 Flexible and expanded cryogenic solutions being well received by several ne
Read more →-CYRX
Feb 5, 2015Cryoport Reports Record Results; Grows Revenue by 50% for the First Nine Months of Fiscal 2015 --- Fiscal 2016 Revenue Guidance of $10MM - $12MM --- Management Conference Call Scheduled for 10AM ET on February 5 th
Cryoport Reports Record Results; Grows Revenue by 50% for the First Nine Months of Fiscal 2015 Fiscal 2016 Revenue Guidance Management Conference Call Scheduled for 10AM ET on February 5th LAKE FOREST, CA - February 5, 2015 - Cryoport, Inc. (CYRX) today announced financial
Read more →-CYRX
Jan 12, 2015Cryoport Appoints Richard J. Berman to its Board of Directors Lake Forest, CA
Appoints Richard J. Berman to its Board of Directors Lake Forest, CA, January 12, 2015 - Cryoport, Inc. (OTCBB:CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines,
Read more →-CYRX
Nov 12, 2014Cryoport Increases Revenue by 65% for the First Six Months of Fiscal 2015 Revenue growth driven by broader customer base, expanded distribution and increased customer utilization - - - Now has collaborative agreements wi
Cryoport Increases Revenue by 65% for the First Six Months of Fiscal 2015 Revenue growth driven by broader expanded distribution and increased customer utilization Now has collaborative agreements with the three major global carriers accounting for over 220 countries. LAKE
Read more →-CYRX
Jul 31, 2014Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 - - - Expanded customer base and increased customer productivity is driving revenue growth and significantly higher margins - - - Finalized internation
Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 Expanded customer base and increased customer productivity is driving revenue growth and significantly higher margins Finalized international agreements with DHL and several global life science companies LA
Read more →-CYRX
Jun 16, 2014Cryoport Announces Appointment of Ramkumar Mandalam, Ph.D. to Board of Directors - - - Mandalam to also join Compensation and Nominating and Governance Committees
Cryoport Announces Appointment of Ramkumar Mandalam, Ph.D. to Board of Directors Mandalam to also join Compensation and Nominating and Governance Committees LAKE FOREST, CA - June 16, 2014 - Cryoport, Inc. (OTC BB: CYRX) ("the Company"), the leading, global provider of adva
Read more →-CYRX
May 19, 2014Cryoport Reports Fourth Consecutive Quarter of Triple Digit Year-over-Year Revenue Growth for Fourth Quarter of 2014 - - - Revenue increases 127% and 142% year-over-year for the three month and twelve month periods ended
Reports Fourth Consecutive Quarter of Triple Digit Year-over-Year Revenue Growth for Fourth Quarter of 2014 127% and 142% year-over-year for the three month and twelve month periods ended March 31, 2014, respectively cryogenic solutions offering being well received by market L
Read more →-CYRX
Sep 17, 2013Cryoport Elects Edward Zecchini to Board of Directors LAKE FOREST, Calif. - September 16 , 2013 - Cryoport, Inc. (OTCBB: CYRX) today announced it has elected Edward J. Zecchini to its Board of Directors. Mr. Zecchini is
Cryoport Elects Edward Zecchini to Board LAKE FOREST, Calif. - September 16, 2013 - Cryoport, Inc. (OTCBB: CYRX) today announced it has elected Edward J. Zecchini to its Board of Directors. Mr. Zecchini is an established technology leader with over thirty years of experience
Read more →-CYRX
Jun 6, 2013Cryoport Doubles Revenues for Fiscal 2013 Sales Growth Continues to Ramp in Fiscal 2014
Cryoport Doubles Revenues for Fiscal 2013 Sales Growth Continues to Ramp LAKE FOREST, CA June 6, 2013 Cryoport, Inc. (OTCBB: CYRX) today announced preliminary financial results for the fiscal fourth quarter and year ended March 31, 2013. Revenues for fiscal 2013 were $1.1 mill
Read more →-CYRX
Apr 1, 2013Cryoport Appoints Richard Rathmann to Board of Directors
Cryoport Appoints Richard Rathmann to Board of Directors LAKE FOREST, CA April 1, 2013 Cryoport, Inc. (OTCBB: CYRX) today announced it has appointed Richard G. Rathmann to its Board of Directors. Mr. Rathmann is an experienced venture fund manager and advisor to life science co
Read more →-CYRX
Nov 5, 2012Cryoport Appoints Jerrell Shelton as President and Chief Executive Officer
Cryoport Appoints Jerrell Shelton as President and Chief Executive Officer LAKE FOREST, CA November 5, 2012 Cryoport, Inc. (OTCBB: CYRX) today announced that Jerrell Shelton has been named President and Chief Executive Officer, effective immediately. Mr. Shelton joined the Comp
Read more →-CYRX
Oct 22, 2012Jerrell Shelton to Join Cryoport s Board of Directors
Jerrell Shelton to Join Cryoport s Board of Directors LAKE FOREST, CA October 22, 2012 Cryoport, Inc. (OTCBB: CYRX) announced that Jerrell Shelton was elected to its Board of Directors today. Mr. Shelton has served on many public and private boards and currently sits on the Smi
Read more →-CYRX
Sep 20, 2012CRYOPORT
CRYOPORT INVESTOR CONFERENCE CALL 2:00 p.m. Eastern time / 11:00 a.m. Pacific time Management dial-in #: 877-407-6180 Thank you. This is Don Markley with LHA. Thank you all for participating on today s call, during which management will provide an update on Cryoport s busines
Read more →-CYRX
Feb 17, 2012CRYOPORT CLOSES PRIVATE PLACEMENT WITH PURCHASE AGREEMENTS FOR $5.0
CRYOPORT CLOSES PRIVATE PLACEMENT WITH PURCHASE AGREEMENTS FOR $5.0 SAN DIEGO, CA February 17, 2012 CryoPort, Inc. (OTCBB: CYRX) today announced it has closed a private placement with various accredited investors for gross proceeds of $5.0 million. The Company obtained agreeme
Read more →-CYRX
Jun 28, 2011CryoPort Names Robert Stefanovich as Chief Financial Officer Sales Team Bolstered with East Coast Senior Sales Directors
CryoPort Names Robert Stefanovich as Chief Financial Officer Sales Team Bolstered with East Coast Senior Sales Directors June 28, 2011 CryoPort, Inc. (OTCBB: CYRX) today announced that it has named Robert S. Stefanovich, 46, as Chief Financial Officer, Treasurer and Corporate
Read more →-CYRX
May 31, 2011CryoPort Names Karen M. Muller to Board of Directors
CryoPort Names Karen M. Muller to May 31, 2011 - CryoPort, Inc. (OTCBB: CYRX) today announced that it has named Karen M. Muller to its Board of Directors. Ms. Muller, 56, is a corporate attorney with more than 25 years of experience as both a company executive and legal couns
Read more →-CYRX
Feb 7, 2011CRYOPORT CLOSES FIRST ROUND OF PRIVATE PLACEMENT WITH PURCHASE AGREEMENTS FOR $4.4
CRYOPORT CLOSES FIRST ROUND OF PRIVATE PLACEMENT WITH PURCHASE AGREEMENTS FOR $4.4 MILLION SAN DIEGO, CA February 7, 2011 CryoPort, Inc. (OTCBB: CYRX) today announced it has closed the first round of a private placement with various accredited investors for $4.4 million. The Co
Read more →-CYRX
Jan 12, 2010CryoPort Announces the Addition of John H. Bonde to Its Board of Directors LAKE FOREST, CA --(
Announces the Addition of John H. Bonde to Its Board of Directors FOREST, CA --(January 12, 2010) - CryoPort, Inc. (OTCBB: CYRX) today announced that John H. Bonde, 64, was elected as a director to the Board on January 7, 2010 and serves as a member of the audit committee. Mr
Read more →Competitive Position
How CYRX ranks across every disease it competes inCompetitive Position is a premium feature
See how CYRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial